Drug name - Veklury
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE46762 | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(6 years from now) | |
| US8318682 | GILEAD SCIENCES INC | 1′substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(6 years from now) | |
| US8008264 | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Sep, 2029
(6 years from now) | |
| US10065958 | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Sep, 2031
(8 years from now) | |
| US9724360 | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Oct, 2035
(13 years from now) | |
| US9949994 | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Oct, 2035
(13 years from now) | |
| CN102046626A | GILEAD SCIENCES INC | Carba-Nucleoside Analogs For Antiviral Treatment |
Sep, 2015
(7 years ago) | |
| CN102015714B | GILEAD SCIENCES INC | 1'-Substitued Carba-Nucleoside Analog For Antiviral Therapy |
Apr, 2029
(6 years from now) | |
| CN102015714A | GILEAD SCIENCES INC | 1'-Substituted Carba-Nucleoside Analogs For Antiviral Treatment |
Apr, 2029
(6 years from now) | |
| CN104262345B | GILEAD SCIENCES INC | Antiviral Therapy For 1 ' - Substituted Carba-Nucleoside Nucleoside Analogues |
Apr, 2029
(6 years from now) | |
| CN104262345A | GILEAD SCIENCES INC | 1'-Substitued Carba-Nucleoside Analog For Antiviral Therapy |
Apr, 2029
(6 years from now) | |
| CN103052631B | GILEAD SCIENCES INC | Method And Composite For Treating Assistant Adhesive Virus Family Virus Infection |
Jul, 2031
(8 years from now) | |
| CN105343098A | GILEAD SCIENCES INC | Method And Composite For Treating Assistant Adhesive Virus Family Virus Infection |
Jul, 2031
(8 years from now) | |
| CN105343098B | GILEAD SCIENCES INC | For Treating Virus Virus Infection Of Secondary Method And Compound |
Jul, 2031
(8 years from now) | |
| CN103052631A | GILEAD SCIENCES INC | Method And Compound For Treating Paramyxoviridae Virus Infection |
Jul, 2031
(8 years from now) | |
| CN107073005A | GILEAD SCIENCES INC | Method Of Treating Filamentous Virus Family Virus Infections |
Oct, 2035
(13 years from now) | |
| CN107073005B | GILEAD SCIENCES INC | Method Of Treating A Virus Infection In A Filamentous Virus |
Oct, 2035
(13 years from now) | |
| IN289041B | GILEAD SCIENCES INC | Carba-Nucleoside Analogs For Antiviral Treatment |
Apr, 2029
(6 years from now) | |
| IN319927B | GILEAD SCIENCES INC | Methods And Compounds For Treating Paramyxoviridae Virus Infections |
Jul, 2031
(8 years from now) | |
| IN201301328P4 | GILEAD SCIENCES INC | Methods And Compounds For Treating Paramyxoviridae Virus Infections |
Jul, 2031
(8 years from now) | |
| EP2937350A1 | GILEAD SCIENCES INC | 1' -Substituted Carba-Nucleoside Analogs For Antiviral Treatment |
Apr, 2029
(6 years from now) | |
| EP2280973B1 | GILEAD SCIENCES INC | Carba-Nucleoside Analogs For Antiviral Treatment |
Apr, 2029
(6 years from now) | |
| EP2937350B1 | GILEAD SCIENCES INC | 1' -Substituted Carba-Nucleoside Analogs For Antiviral Treatment |
Apr, 2029
(6 years from now) | |
| EP2280973A1 | GILEAD SCIENCES INC | Carba-Nucleoside Analogs For Antiviral Treatment |
Apr, 2029
(6 years from now) | |
| EP2268642B1 | GILEAD SCIENCES INC | 1' -Substituted Carba-Nucleoside Analogs For Antiviral Treatment |
Apr, 2029
(6 years from now) | |
| EP2268642A1 | GILEAD SCIENCES INC | 1' -Substituted Carba-Nucleoside Analogs For Antiviral Treatment |
Apr, 2029
(6 years from now) | |
| EP2595980A1 | GILEAD SCIENCES INC | Methods And Compounds For Treating Paramyxoviridae Virus Infections |
Jul, 2031
(8 years from now) | |
| EP2595980B1 | GILEAD SCIENCES INC | Methods And Compounds For Treating Paramyxoviridae Virus Infections |
Jul, 2031
(8 years from now) | |
| EP3212175B1 | GILEAD SCIENCES INC | Methods For The Preparation Of Ribosides |
Oct, 2035
(13 years from now) | |
| EP3212174A1 | GILEAD SCIENCES INC | Methods For Treating Filoviridae Virus Infections |
Oct, 2035
(13 years from now) | |
| EP3212174B1 | GILEAD SCIENCES INC | Methods For Treating Filoviridae Virus Infections |
Oct, 2035
(13 years from now) | |
| EP3366295B1 | GILEAD SCIENCES INC | Methods For Treating Filoviridae Virus Infections |
Oct, 2035
(13 years from now) | |
| EP3366295A1 | GILEAD SCIENCES INC | Methods For Treating Filoviridae Virus Infections |
Oct, 2035
(13 years from now) | |
| EP3212175A1 | GILEAD SCIENCES INC | Methods For The Preparation Of Ribosides |
Oct, 2035
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10695361 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(13 years from now) | |
| US11007208 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(13 years from now) | |
| US10675296 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(15 years from now) | |
Drugs and Companies using REMDESIVIR ingredient
Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg); Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg); treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 100MG/VIAL | POWDER;INTRAVENOUS | Prescription |
| 100MG/20ML (5MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.